Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Shukun Technology (数坤网络科技) Pre-IPO: Promising AI-Assisted Diagnosis

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Infervision Medical Technology / Equity Capital Markets

Infervision, a China-based AI-assisted medical imaging solution company, plans to raise up to USD 300m via a Hong Kong listing.The company's AI-medical screening and diagnostic products mainly focus on the pulmonary segment. Upon reading the company's disclosure on its core products, we are of the view that it does not provide detailed enough data closure for investors to determine if its accuracy is superior to its competitors. The company does not have a strong pre-IPO investor backing and the experience of the management team is mediocre. We do not think that the fundamentals of the company are attractive.

Infervision, a China-based AI-assisted medical imaging solution company, plans to raise up to USD 300m via a Hong Kong listing.The company's AI-medical screening and diagnostic products mainly focus on the pulmonary segment. Upon reading the company's disclosure on its core products, we are of the view that it does not provide detailed enough data closure for investors to determine if its accuracy is superior to its competitors. The company does not have a strong pre-IPO investor backing and the experience of the management team is mediocre. We do not think that the fundamentals of the company are attractive.

Shukun (Beijing) Technology (1702626D CH)

Infervision (推想医疗科技) Pre-IPO: Lacking Disclosure